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1 Introduction
The delivery of drugs for pharmaceutical and medical applications is usually achieved
through a variety of drug delivery systems such as injections, tablets and sprays.
These systems must deliver the correct dose of the drug in an efficient manner,
that is: a controlled delivery which maintains the optimal concentration within the
bloodstream in order to be therapeutically effective for reasonable periods of time
[13]. Typically, such delivery systems produce an initial rise of drug concentration
reaching a peak after which it falls off so that another dose is required to maintain
drug effectiveness. At times this concentration may rise above the maximum ther-
apeutic range, into the possibly toxic, while at others it falls below the minimum
therapeutic level making the drug ineffective.
The ability to release the drug at therapeutically effective levels and maintain these
levels for longer periods of time while avoiding such oscillatory behaviour is one of
the objectives of a controlled release system. This allows the drug to be adminis-
tered in a single dose while reducing the possibility of side effects. This requires
the design of new systems with an understanding of their release behaviour while
optimising their release kinetics [11].
The majority of controlled release devices consist of drugs dispersed within a poly-
meric carrier, commonly hydrogels.
1.1 Hydrogels
Hydrogels are three-dimensional, water-swollen structures mainly composed of hy-
drophilic polymeric networks containing chemical or physical cross-links [12]. Hy-
drogels can imbibe water or other biofluids with some being able to swell to ten times
   
their original volume. Hydrogels have been used for medical applications for some
time. Upon absorption of water a hydrogel changes from its often dry non-swollen
state to a gel-like state which exhibits rubbery behaviour with an ability to resemble
bodily tissues therefore possessing good biocompatibility [12]. The medical appli-
cations of hydrogels inlude: the use of PHEMA (poly-2-hydroxyethyl methacrylate)
for soft contact lenses, PVA (poly-vinyl-alcohol) in artificial cartilage and Cellulose
acetate for artificial kidneys as well as for biosensors, sutures and dental materials
[14]. However, it is their ability to act as drug release devices which is the focus of
this report.
1.2 Drug Release Systems
Drugs may be enclosed or immersed within a hydrogel and correspond to several
different types of controlled release systems: diffusion-controlled systems, swelling
controlled systems, chemically controlled systems and environmentally responsive
systems [14]. We are mainly interested in diffusion and swelling-controlled systems.
1.2.1 Diffusion-Controlled Release Systems
There are two types of diffusion controlled release systems: reservoir devices and
matrix devices. In each case the release of the drug occurs by diffusion through the
hydrogel mesh or the water-filled pores.
1. Reservoir Systems: a reservoir delivery system consists of a drug core enclosed
in a hydrogel membrane, usually in the form of capsules, cylinders, spheres
or slabs. In order to maintain a constant release rate the drug concentration
difference must remain constant. This is achieved by concentrating the drug
in the centre of the device. The drug release behaviour of the device is shown
in Figure 1.
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Figure 1: Drug release from a reservoir system by diffusion through the hydrogel
membrane.
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2. Matrix Systems: in matrix systems the drug is dispersed throughout the hy-
drogel lying within the three-dimensional structure of the polymer. Matrix
tablets are constructed through a compression of a mixture of drug and poly-
mer powders. Drug release occurs through the macromolecular mesh or water-
filled pores. Note that the release rate is here proportional to the square root
of time initially rather than the constant time-independent rate available with
reservoir systems. The drug release characteristics of matrix devices is shown
in Figure 2.
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Figure 2: Drug release from a matrix system by diffusion through the entire hydrogel.
1.2.2 Swelling-Controlled Release Systems
In swelling-controlled release systems the drug is dispersed within a glassy polymer
as in a matrix device. Once the polymer comes into contact with water or another
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Figure 3: .
biofluid it begins to swell. The glass transition temperature of the polymer is lowered
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allowing a relaxation of molecular chains so that the drug can now diffuse out of
the swollen rubbery area of the polymer [14]. Figure 3 shows how the swelling edge
of the tablet expands beyond its original boundary. This is also known as Case II
transport and is characterised by constant, i.e. time-independent, release kinetics.
In some cases a combination of swelling controlled release as well as diffusion occurs,
this is known as anomalous transport [13].
2 Diffusion in Hydrogels
Once a matrix delivery device comes in contact with a surrounding biofluid a con-
centration gradient will exist between the dispersed drug within the hydrogel and
the ambient fluid. The transport of drug is now possible from a high concentration
through the hydrogel into the surrounding fluid, at a lower concentration [15]. The
flux of drug, J, is proportional to the driving force, ∇c (concentration gradient) as:
J = −D∇c
where D, the diffusion coefficient of the drug in the polymer, cm2/s, c is the concen-
tration of the drug in the polymer, mol/cm3, and J is the molar flux of the drug in
mol/cm2s. Usually the release rate is time dependent so that the release behaviour
is determined from the unsteady diffusion problem:
∂c
∂t
= −∇ · J = ∇ · (D∇c) (1)
with associated boundary and initial conditions. Note that here the diffusion co-
efficient may be space dependent. This equation represents the one-dimensional
transport of drug with non-moving boundaries.
Typically, the problem considered is the diffusion of drug out of the hydrogel, pos-
sessing a high concentration, into the surrounding fluid, possessing a low concentra-
tion. For simplicity the initial concentration inside the hydrogel is given as unity
throughout whereas the concentration in the ambient fluid is assumed to be zero.
The boundary conditions at the hydrogel boundary remain zero, these are so-called
perfect sink conditions such that the drug is immediately carried away into the fluid
so that a concentration gradient always exists at the interface between the hydrogel
and the ambient fluid. This is summarised in Figure 4.
2.1 Drug Release from Hydrogels
Equation (1) is a diffusion equation with a non-moving boundary. That is, the
hydrogel is not swelling. It describes the diffusion of drug out of the hydrogel while
the boundary is static, this will be known as Static Drug Delivery. On the other
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Figure 4: Initial conditions in the hydrogel/biofluid system showing sink conditions
at and beyond the hydrogel/fluid boundary.
hand when the hydrogel is undergoing swelling the process will be called Dynamic
Drug Delivery.
2.1.1 Static Drug Delivery
The solution of the diffusion equation (1) may be carried out in several ways using
either Laplace transforms or separation of variables, especially in the simple case
of constant diffusion coefficient, ∇D ≡ 0. The information obtained from these
solutions includes [12]:
1. drug concentration profiles in the polymer during release which are obtained
directly from the solution of equation (1).
2. the amount or mass of drug released Mt which may be normalised with respect
to the amount released at infinite time M∞, i.e. the fractional release of the
drug, Mt/M∞.
Peppas [1] has shown that, for diffusion with a constant diffusion coefficient and
perfect sink conditions, the fractional drug release for short times is given by:
Mt
M∞
= ktn (2)
for k a constant and the diffusional exponent n is 0.5. This is confirmed by experi-
mental results which distinctly show drug release behaviour that is linear with
√
t,
at least initially.
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2.1.2 Dynamic Drug Delivery
It is well known that hydrogels will swell upon contact with water. The process
of diffusion out of the polymer while this is occurring has not yet been fully re-
searched and remains an ongoing research topic. Experimental results have also
shown that the drug release behaviour from a swelling polymer is different from that
of a non-swelling one. It may undergo both Case II and anomalous transport which
is demonstrated by time-independent, zero order release kinetics, or time-dependent
release behaviour with a diffusional exponent between 0.5 and 1, respectively.
Although the consequences of swelling behaviour have been demonstrated exper-
imentally little theoretical work has investigated this process. One aspect of the
swelling behaviour of hydrogels is how the diffusion characteristics change as the
boundary of the original hydrogel grows. In addition, it is known that the diffu-
sion coefficient may be dependent on the degree of swelling [15, 11]. If the degree
of swelling can be measured by the convective velocity of the moving boundary it
becomes time dependent. These two aspects of diffusion from swelling hydrogels is
the reason for the current investigation.
2.2 Aims of the Current Study
This report is concerned with controlled-release systems of the matrix type. Given
the possibility of catastrophic failure of reservoir systems and the sudden release
of the entire drug contents into the body, matrix systems are prefered. As noted
above matrix systems are usually drug delivery devices which use a hydrogel as the
carrier of the dispersed drug. Hydrogels will swell upon contact with water or other
biofluids so that a model describing swelling behaviour in conjunction with diffusion
is necessary. As well, the diffusion coefficient may become time-dependent which
requires further study.
The aims of the current study are to derive and analyse a model for hydrogel drug
delivery devices which include:
1. Diffusion processes in a swelling hydrogel.
2. The variation of the diffusion coefficient with the degree of swelling.
3 Drug Diffusion in a Swelling Hydrogel
The release of drugs for medical applications is often carried out by encapsulating
the drug within a polymer which may swell upon absorption of fluid. Define the
concentration of the drug within the polymer, at any time in a three dimensional
domain, as c = c(x, y, z, t). The drug diffuses out of the domain at the boundaries
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which may themselves swell or grow as water/fluids are absorbed. The general
advection-diffusion equation for a growing domain is given by [8]:
∂c
∂t
= ∇ · (D∇c)−∇ · (cu)
which becomes, for a constant diffusion coefficient, ∇D ≡ 0:
∂c
∂t
= D∇2c−∇ · (cu)
In only one dimension, u = ui this reads:
∂c
∂t
= D
∂2c
∂x2
− u ∂c
∂x
− ∂u
∂x
c
The term on the left expresses the local rate of change of concentration over time,
whereas the three terms on the right hand side express the advection of elemental
volumes moving with the flow i.e. ucx, the dilution term uxc is due to local volume
change and the first term expresses the diffusion of the concentration.
Typically, such release occurs via the diffusion of the drug from within the polymer
through the boundary. For simplicity the initial drug concentration is assumed to
be unity in the whole domain, 0 < x < X(0). The concentration at the growing
boundary x = X(t) = Lf(t) (where f(t) > 1 for all time) at any time is assumed
zero, here making use of sink conditions. The problem is symmetric about the
boundaries and can then be expressed as :
∂c
∂t
= D
∂2c
∂x2
− c∂u
∂x
− u ∂c
∂x
in 0 < x < X(t), t > 0 (3)
subject to:
c(x, 0) = 1 0 < x < X(0)
X(0) = L
∂c
∂x
(0, t) = 0
c(X(t), t) = 0
}
for t > 0
(4)
The initial condition is shown in Figure 5.
3.1 Uniform Growth Velocity in 0 ≤ x ≤ X(t)
At time t = 0 two facts are known: (i) the velocity at the left edge of the domain
u(0, 0) = 0 and (ii) that of the right edge u(X(0), 0) = X˙(0) 6= 0. For t > 0
the left edge velocity remains clamped at zero whereas the right edge grows i.e.
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Figure 5: The initial concentration c(x, 0) = 1, in 0 < x < X(t) with boundary
conditions ∂c(0, t)/∂x = 0 and c(X(t), t) = 0 for t > 0.
u(X(t), t) = X˙(t). A velocity gradient must exist across the domain. Therefore we
may immediately say that:
u(X(t), t)− u(0, t) =
∫ X(t)
0
∂u
∂x
dx
or:
dX
dt
=
∫ X(t)
0
∂u
∂x
dx
We adopt the simple model of uniform growth, see [9, 10, 5], i.e. ∂u/∂x is indepen-
dent of x and only a function of t, or ∂u/∂x = σ(t), we have:
X˙(t) = σ(t)
∫ X(t)
0
dx = X(t)σ(t)⇒ σ(t) = X˙
X
therefore:
∂u
∂x
=
X˙
X
, and u(x, t) =
X˙
X
x
3.1.1 Final Advection-Diffusion Equation
The PDE (3) becomes:
∂c
∂t
= D
∂2c
∂x2
−
(
X˙
X
x
)
∂c
∂x
−
(
X˙
X
)
c in 0 < x < X(t), t > 0 (5)
c(x, 0) = 1 0 < x < X(0)
X(0) = L
∂c
∂x
(0, t) = 0
c(X(t), t) = 0
}
for t > 0
(6)
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3.1.2 The Landau Transformation
The convective term may be removed by use of the Landau transformation [7], so
that the system (5), (6) is now, see Appendix 6.1
∂c
∂τ
=
D
X2
∂2c
∂ζ2
− X˙
X
c in 0 < ζ < 1, τ > 0 (7)
c(ζ, 0) = 1 0 < ζ < 1
∂c
∂ζ
(0, τ) = 0
c(1, τ) = 0
}
for τ > 0
(8)
this is the one dimensional advection-diffusion equation in a growing domain.
3.2 Concentration and Drug Release Profiles
3.2.1 Solution in Terms of Trigonometric Functions
The solution may be obtained by separation of variables, see Appendix 6.2, giving
c(ζ, τ) =
4
pi
∞∑
n=0
(−1)n
(2n+ 1)
L
X(τ)
cos
(
(2n+ 1)piζ
2
)
e−D(
(2n+1)pi
2 )
2 ∫ τ
0
X−2 dt (9)
or in terms of the original variables:
c(x, t) =
4
pi
∞∑
n=0
(−1)n
(2n+ 1)
L
X(t)
cos
(
(2n+ 1)pix
2X(t)
)
e−D(
(2n+1)pi
2 )
2 ∫ t
0
X(t′)−2 dt′
3.2.2 Fractional Drug Release
Now define the fractional drug release in terms of the original variables as:
M(τ) = 1−
∫X(τ)
0 c(x, τ) dx∫X(0)
0 c(x, 0) dx
which relates the ratio of the total mass in the volume X(τ) to the initial mass in
volume L. This ratio must decrease as the volume increases. In terms of the new
variables ζ and τ :
M(τ) = 1−
∫ 1
0 c(ζ, τ)X(τ) dζ∫ 1
0 c(ζ, 0)X(0) dζ
= 1− X(τ)
L
∫ 1
0
c(ζ, τ) dζ
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therefore inserting the solution (9) we have:
M(τ) = 1− X
L
∫ 1
0
4
pi
∞∑
n=0
(−1)n
(2n+ 1)
L
X
cos
(
(2n+ 1)piζ
2
)
e−D(
(2n+1)pi
2 )
2 ∫ τ
0
X−2 dt dζ
= 1− 4
pi
∞∑
n=0
(−1)n
(2n+ 1)
e−D(
(2n+1)pi
2 )
2 ∫ τ
0
X−2 dt
∫ 1
0
cos
(
(2n+ 1)piζ
2
)
dζ
so that:
M(τ) = 1−
∞∑
n=0
8
(2n+ 1)2pi2
e−D(
(2n+1)pi
2 )
2 ∫ τ
0
X−2 dt (10)
again, in terms of the original variables we have:
M(t) = 1−
∞∑
n=0
8
(2n+ 1)2pi2
e−D(
(2n+1)pi
2 )
2 ∫ t
0
X(t′)−2 dt′
note that the fractional drug release always depends on the flux on the outer bound-
ary at ζ = 1, see Appendix 6.3. This also means that if the flux condition at ζ = 1
is zero, cζ(1, τ) = 0, then so is the fractional drug release for all time.
4 Static and Dynamic Drug Release
Define the case where the domain is stationary as the static case, i.e. X˙ = Lf˙ = 0,
then
MS(τ) = −D
L2
∫ τ
0
cζ(1, t) dt
and the dynamic case where X˙ = Lf˙ 6= 0:
MD(τ) = −D
L2
∫ τ
0
cζ(1, t)
f(t)
dt
This implies that:
MD(τ)−MS(τ) = −D
L2
∫ τ
0
(
1− 1
f(t)
)
|cζ(1, t)| dt
since the flux at the outer boundary ζ = 1 is always negative. And for f(t) > 1 for
all t the term 1− 1/f > 0 so that this integral is always positive which implies that
the difference between the dynamic and static drug release is always negative, i.e.
in terms of original variables
MD(t) < MS(t)
for all time. This means that the dynamic drug release is never as much as the static
release.
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4.1 Static Drug Release: X˙ = 0
For the case of a stationary boundary, i.e. a non growing boundary having X(τ) = L
for all time the solution (25) becomes:
c(ζ, τ) =
4
pi
∞∑
n=0
(−1)n
(2n+ 1)
cos
(
(2n+ 1)piζ
2
)
e−D(
(2n+1)pi
2L )
2
τ
with an associated fractional drug release as (in terms of t)
MS(t) = 1−
∞∑
n=0
8
(2n+ 1)2pi2
e−D(
(2n+1)pi
2L )
2
t (11)
4.1.1 Fractional Drug Release for Short Times
The above solution for the stationary boundary case (11) may be rewritten in terms
of complimentary error functions:
MS(t) = 2
√
Dt
L2
[
1√
pi
+ 2
∞∑
n=1
(−1)nierfc
(
nL√
Dt
)]
(12)
Note that by definition [2]:
ierfc x =
e−x
2
√
pi
− xerfc x
so that for large x, erfc x→ 0, e−x2 → 0 and so ierfc x→ 0. Therefore
lim
t→0 ierfc
(
nL√
Dt
)
= 0
so that for t small
MS(t) ' 2
√
Dt
L2
1√
pi
= kt
1
2 (13)
where k = (2/L)
√
D/pi. Reproducing the solution (2) obtained in [1].
4.1.2 The Characteristics of Fractional Drug Release
The graphs of Figure 6 show fractional drug release M(τ) a function of (a) τ and
(b) τ 1/2. Clearly for small times studied τ : 0→ 0.25 s the fractional drug release is
directly proportional to the square root of time.
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(a) (b)
Figure 6: Fractional drug release M(τ) as a function of (a) τ and (b)
√
τ for the
static case with L = D = 1.
4.1.3 Fractional Drug Release: Comparison over Longer Times
Consider now how the solution for small times (13), i.e.
MS(τ) =
2
L
√
D
pi
τ 1/2
compares to the analytical (12) solution for longer times. Figure 7 shows how the
Figure 7: Deviation of the fractional drug release small time solution compared with
the solution for longer times as a function of τ 1/2.
12
          
small time solution compares to the analytical solution over longer times. Figure
6(b) indicates that the small time solution starts to deviate from the long time case
beyond about τ 1/2 = 0.5. This is confirmed in Figure 7 where the relative difference
between the analytical solution and the small time solution also starts to vary at
around τ 1/2 = 0.5. Here we have used:
Rel. % Diff =
∣∣∣∣∣∣
MS(τ)− 2
√
Dτ/piL2
MS(τ)
∣∣∣∣∣∣× 100
4.2 Dynamic Drug Release: X˙ 6= 0
We may choose various possible growth functions for X(τ). Typical choices include
linear growth, exponential growth and logistic growth, see Landman et al [9]. The
first two: linear and exponential growth are ever growing domains which tend to
an infinite volume as time increases; the third, logistic growth, expands the volume
only to a multiple of the original length mL. Whereas the r parameter acts as a
growth factor, expressing how fast the volume grows in the first two cases, the third
case r is a parameter which speeds up or slows down the expansion towards the final
volume mL.
4.2.1 Linear Growth
This represents a function of the form
X(τ) = L(1 + rτ), X˙ = Lr
where r is the growth factor. The integral∫ τ
0
X(t)−2 dt =
τ
L2(1 + rτ)
the fractional drug release is
MD(τ) = 1−
∞∑
n=0
8
(2n+ 1)2pi2
e−D(
(2n+1)pi
2L )
2
( τ1+rτ ) (14)
Note that as τ →∞ the mass of drug released attains a constant value given by:
Mrel = 1−
∞∑
n=0
8
(2n+ 1)2pi2
e−
D
r (
(2n+1)pi
2L )
2
(15)
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4.2.2 Exponential Growth
This represents a function of the form:
X(τ) = Lerτ , X˙ = Lrerτ
The integral ∫ τ
0
X(t)−2 dt =
1
2rL2
(1− e−2rτ )
the fractional drug release is
MD(τ) = 1−
∞∑
n=0
8
(2n+ 1)2pi2
e
−D( (2n+1)pi2L )
2
(
(1−e−2rτ )
2r
)
(16)
The mass of drug released reaches a constant value as time increases given by:
Mrel = 1−
∞∑
n=0
8
(2n+ 1)2pi2
e−
D
2r (
(2n+1)pi
2L )
2
(17)
4.2.3 Logistic Growth
This represents a function of the form:
X(τ) =
Lerτ
1 + (1/m)(erτ − 1) , X˙ =
Lrerτ (1− 1/m)
[1 + (1/m)(erτ − 1)]2
where m is the ratio of final to initial lengths. The integral∫ τ
0
X(t)−2 dt =
1
2L2m2r
[
(m− 1)2(1− e−2rτ ) + 4(m− 1)(1− e−rτ ) + 2rτ
]
so that the fractional drug release reads:
MD(τ) = 1−
∞∑
n=0
8
(2n+ 1)2pi2
e−
D
2r (
(2n+1)pi
2mL )
2
[(m−1)2(1−e−2rτ )+4(m−1)(1−e−rτ )+2rτ] (18)
In this case for large times the mass of drug released looks like:
Mrel = 1−
∞∑
n=0
8
(2n+ 1)2pi2
e−
D
2r (
(2n+1)pi
2mL )
2
[(m−1)2+4(m−1)+2rτ]
= 1−
∞∑
n=0
8e−
D
2r (
(2n+1)pi
2mL )
2
[(m−1)2+4(m−1)]
(2n+ 1)2pi2
e−D(
(2n+1)pi
2mL )
2
τ
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4.2.4 Results : The Growing Boundary
For the case where the boundary is growing and this growth function is given be-
forehand, the solution may be found analytically, involving the evaluation of an
integral in equation (10). We study two types of growth functions here: (i) growth
functions which increase indefinitely and (ii) growth functions which increase up to
a certain size but no further. The second of these is the more realistic and more
correctly represents the swelling of the polymer. The swelling is assumed at first to
be rapid and then gradually ebbing away to a given multiple of the initial volume.
The characteristic case is logistic growth. Domain growth is shown in Figure 8 for
Figure 8: Growth functions of the indefinite type: linear (solid), exponential (dot-
dash) and the finite type: logistic (dotted) for growth factors from r = 0 to r = 2.
both the two indefinite types: linear and exponential and the finite type: logistic for
three values of growth factor r = 0→ 2 and m = 3 for the logistic case. The r = 0
case is the same for each growth function type. Note that for the two indefinite
types the growth factor r represents how fast the volume increases over time with
the exponential case increasing at a much faster rate than the linear, see Figure 8
(dot-dash and solid lines). For the finite type, the logistic case, the parameter r
represents how quickly the volume increases towards its final size which is expressed
by the ratio of final to initial volume m, see Figure 8 (dotted line). The larger the
value of r the faster the final volume is reached.
Typical results for the fractional drug release M(τ) over time is shown in Figure 9
for the linear, Figure 9(a), exponential, Figure 9(b) and logistic, Figure 9(c) cases.
For each case we chose a space step of ∆ζ = 1/50 and time step of ∆τ = 1/502 with
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an initial length L = 1 and diffusion coefficient D = 1. Each graph indicates the
maximum volume, as a multiple of L, reached for each value of r used.
(a) Linear Growth (b) Exponential Growth
(c) Logistic Growth
Figure 9: Fractional drug Release M(τ) over time as a function of (a) linear, (b)
exponential and (c) logistic growth for various values of the growth factor r and
m = 3; with initial length L = 1, diffusion coefficient D = 1 for a grid of space step
size ∆ζ = 1/50 and time step ∆τ = 1/502.
4.2.5 Linear Drug Release
Typically, the r = 0 case represents the diffusion of the drug out of the constant
volume L over time. This remains linear in
√
τ until about
√
τ = 0.5 after which the
rate of drug release decreases until at around
√
τ = 1.5 all of the drug has diffused
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out (i.e. when M(τ) ' 1). Compare this to the drug release as the volume increases.
It is clear that for all cases where the volume increases with time (and r > 0) the
drug release is less than for the constant volume case r = 0. In fact, over the times
considered none of the r > 0 cases release all of the drug. It appears that as r
increases less and less of the drug is released tending to a constant value of about
M(τ) = 1/2. From equation (27) we know that for long times:
MD(τ) = 1− 8
pi2
lim
τ→∞ e
−D
r (
pi
2L)
2
= 1− 8
pi2
e−
D
r (
pi
2L)
2
so that for L = D = 1, Mrel = 1 − 8pi2 e−
pi2
4r . The results are shown in Table 1.
They agree well with those of Figure 9(a). This shows that in some cases where the
boundary grows at a rapid rate not all of the drug is released from the polymer.
4.2.6 Exponential Drug Release
The aforesaid comments apply even more to the exponential case where all of the
r > 0 cases release the drug at a much smaller rate than the r = 0 case and also at
smaller rates than the linear case with the same growth factor r. Use of (27) for the
exponential case implies
Mrel = 1− 8
pi2
lim
τ→∞ e
−D
2r (
pi
2L)
2
with L = D = 1:
Mrel ' 1− 8
pi2
e−
pi2
8r
The results are shown in Table 1. This again agrees well with the results of Figure
9(b).
4.2.7 Logistic Drug Release
The logistic drug release behaviour is significantly different from that of the other
two cases. This time the r > 0 cases all still release drug at a smaller rate than
the r = 0 case but do not remain at near constant values for long periods of time.
Instead there is a decrease in slope which then appears to become linear after a
certain characteristic time. This time is smaller as r increases. It is also clear that
in all of the logistic cases the drug is released more quickly than in the other cases
with all of the various r cases converging to total drug release in a characteristic
17
      
static linear exponential logistic
r Mrel Mrel Mrel Mrel
0 1.00 1.00 1.00 1.00
1 NA 0.93 0.76 1.00
2 NA 0.76 0.64 1.00
3 NA 0.64 0.56 1.00
4 NA 0.56 0.40 1.00
Table 1: Table showing the amount of drug released for large times. Here, NA
means Not Applicable.
time seemingly around
√
τ ' 2.5.
Equation (27) shows that for L = D = 1 and m = 3:
Mrel ' 1− 8
pi2
e−
pi2
36r
[6+rτ ]
so that all the drug will eventually diffuse out. In fact it is easy to calculate that
99% of the mass will diffuse out by:
τ99 = −6
r
− 36
pi2
ln
(
pi2√
800
)
which gives:
r = 1 : τ99 ' 10
r = 2 : τ99 ' 13
r = 3 : τ99 ' 14
r = 4 : τ99 ' 14.5
although by τ ' 2.5, the r = 1, 2, 3, 4 cases have expended M = 92, 82, 76, 73 %
respectively. Table 1 shows how much of the drug has been released over long times.
The static case does not depend on r of course although the r = 0 case represents
the static case and like the logistic case all of the drug has been released. In both
the linear and exponential cases all of the drug is never completely released.
Note that in all cases the drug release is linear with
√
τ for a time of
√
τ ' 0.2
after which each of the curves diverge. As regards the rate at which the drug is
released over time, we find that the linear and exponential cases both release the
drug linearly in
√
τ until about
√
τ ' 0.2 after which there is a marked decrease in
the rate at which the drug is released. It is clear that the case which represents the
most continuous linear drug release rate for both the linear and exponential cases
is the r = 0 case. In this case the rate of drug released remains constant, with√
τ , for the longest period. If, on the other hand, it is required that the drug be
18
     
released at a slower rate as the polymer swells the larger swell rates are the better
choice. Similarly, if it is required that the amount of drug released remains constant
for as long as possible these higher rates are the better choice, especially for the
exponential case. A polymer which obeys these kind of swell rates is then required.
On the other hand the logistic case possesses no such varied behaviour. In all cases
of r the behaviour is similar with the drug being released at similar rates although
lower as the polymer swells.
5 Time Dependent Diffusion Coefficient
Consider the diffusion coefficient as a function of domain expansion ratio X(t)/L
D = D
(
X(t)
L
)
= D(t)
since X(t) is a function of t. Now the original PDE reads:
∂c
∂t
= D
∂2c
∂x2
−
(
X˙
X
x
)
∂c
∂x
−
(
X˙
X
)
c in 0 < x < X(t), t > 0
c(x, 0) = 1 0 < x < X(0)
X(0) = L
∂c
∂x
(0, t) = 0
c(X(t), t) = 0
}
for t > 0
Note that here D is a function of t only not x. Now define a new time variable [3]
as
T =
∫ t
0
D(t′) dt′,
dT
dt
= D(t)
then the time derivatives may be transformed as
∂c
∂t
=
∂c
∂T
dT
dt
= D(t)
∂c
∂T
,
dX
dt
= D(t)
dX
dT
so that we have:
∂c
∂T
=
∂2c
∂x2
− x
(
X˙
X
)
∂c
∂x
−
(
X˙
X
)
c in 0 < x < X(T ), T > 0
c(x, 0) = 1 0 < x < X(0)
X(0) = L
∂c
∂x
(0, T ) = 0
c(X(T ), T ) = 0
}
for T > 0
19
      
where X˙ = dX/dT . Now using the Landau transformation ζ = x/X(T ), τ = T , we
have:
∂c
∂τ
=
1
X2
∂2c
∂ζ2
−
(
X˙
X
)
c in 0 < ζ < 1, τ > 0 (19)
c(ζ, 0) = 1 0 < ζ < 1
∂c
∂ζ
(0, τ) = 0
c(1, τ) = 0
}
for τ > 0
(20)
which may be solved for to get in terms of x and T :
c(x, T ) =
4
pi
∞∑
n=0
(−1)n
(2n+ 1)
L
X(T )
cos
(
(2n+ 1)pix
2X(T )
)
e−(
(2n+1)pi
2 )
2 ∫ T
0
X−2 dt (21)
and for the fractional drug release as :
M(T ) = 1−
∞∑
n=0
8
(2n+ 1)2pi2
e−(
(2n+1)pi
2 )
2 ∫ T
0
X−2 dt (22)
5.1 Expansion of D for Small Times
The time dependent diffusion coefficient may be expanded in a Taylor series about
t = 0 up to second order in time, see Appendix 6.6, and using the fact that X(t) =
Lf(t) with f(0) = 1
D(t) =
1
L2
[
D(1)t+
f˙(0)
2
(
D′(1)− 2D(1)2
)
t2
]
so that for small time the fractional release reads:
M(t) = 1−
∞∑
n=0
8
(2n+ 1)2pi2
e
−( (2n+1)pi2L )
2
[
D(1)t+
f˙(0)
2 (D′(1)−2D(1)2)t2
]
this is approximated by:
M(t) ' 2
L
√
D(1)
pi
t
1
2
[
1 +
f˙(0)
4
(
D′(1)
D(1)
− 2D(1)
)
t
]
which approximates the earlier obtained expression for small times when D is con-
stant. Note that when D′(1) = 0, i.e. when the diffusion coefficient is not increasing
with time, we have:
M(t) ' 2
L
√
D(1)
pi
t1/2
[
1− 1
2
f˙(0)D(1)t
]
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the above also shows that higher order terms are of relevance only when the domain
is expanding, i.e. when f˙ 6= 0. Note also that this produces a release relationship
of the form
M(t) ' k1t1/2 + k2t3/2 (23)
where this is usually interpreted to imply a diffusion-controlled process k1t
1/2 and
an advective (read relaxation)-controlled transport process [14]. Whereas the first
term in (23) is a diffusion process, the second term is a combination of advection
and diffusion and canot be directly related to empirical models which assume two
separate contributions with the second being of the form kt. This cannot be expected
in this model given that the second term has contributions both from diffusion and
advection and that the model does not solve a Stefan problem where the moving
front is obtained as part of the solution procedure. The present model assumes
simple boundary growth and observes its consequences.
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6 Appendix
6.1 The Landau Transformation
The Landau transformation is defined by
ζ =
x
X(t)
, τ = t
the diffusion equation (5) is transformed with the use of the new variables ζ and τ .
The derivatives become:
∂c
∂t
=
∂c
∂ζ
∂ζ
∂t
+
∂c
∂τ
∂τ
∂t
= − x
X2
∂c
∂ζ
+
∂c
∂τ
= −ζ X˙
X
∂c
∂ζ
+
∂c
∂τ
similarly:
∂c
∂x
=
∂c
∂ζ
∂ζ
∂x
=
1
X
∂c
∂ζ
so that:
∂2c
∂x2
=
1
X2
∂2c
∂ζ2
The new domain is now given by:
x : 0→ X(t), ζ : 0→ 1
and the new diffusion equation becomes:
−ζ X˙
X
∂c
∂ζ
+
∂c
∂τ
=
D
X2
∂2c
∂ζ2
− ζ X˙
X
∂c
∂ζ
− X˙
X
c in 0 < ζ < 1, τ > 0
c(ζ, 0) = 1 0 < ζ < 1
∂c
∂ζ
(0, t) = 0
c(1, t) = 0
}
for τ > 0
6.2 Analytic Solution for c(ζ, τ) by Separation of Variables
This problem (7), (8) is solvable via a separation of variables as follows:
c(ζ, t) = A(ζ)B(τ)
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giving:
AB˙ =
D
X2
A′′B − X˙
X
AB
divide through by AB and rearrange to get all time dependent functions on the left
and space dependent on the right:
X2
D
B˙
B
+
X˙X
D
=
A′′
A
= −λ2
the two ordinary differential equations are:
B˙ +
(
X˙
X
+
λ2D
X2
)
B = 0
and
A′′ + λ2A = 0
6.2.1 The Solution for A(ζ)
The ODE above now reads:
A′′ + λ2A = 0
subject to the boundary conditions:
A′(0) = 0, A(1) = 0
This may be solved in terms of sines and cosines:
A(ζ) = a1 sinλζ + a2 cosλζ
applying the BCs we have:
A′(0) = λ(a1 + 0) = 0,⇒ a1 = 0, for λ 6= 0
therefore
A(ζ) = a2 cosλ, so that A(1) = a2 cosλ = 0
so λ = (2n+ 1)pi/2 and the solution reads:
A(ζ) = a2 cos
(2n+ 1)piζ
2
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6.2.2 The Solution for B(τ)
We have:
dB
dτ
= −
(
X˙
X
+
λ2D
X2
)
B
giving:
1
B
dB = −
(
X˙
X
+
λ2D
X2
)
dτ
or
lnB = −
∫ τ
0
X˙
X
+
λ2D
X2
dt+ lnC
= − ln X(t)|τ0 −Dλ2
∫ τ
0
X−2 dt+ lnC
ln
(
BX
CL
)
= −Dλ2
∫ τ
0
X−2 dt
using X(0) = L, so that:
B(τ) =
CL
X(τ)
e−Dλ
2
∫ τ
0
X−2 dt
6.2.3 The Full Solution
The final complete solution is expressed via a superposition as:
c(ζ, τ) =
∞∑
n=0
Cn
L
X(τ)
cos
(
(2n+ 1)piζ
2
)
e−D(
(2n+1)pi
2 )
2 ∫ τ
0
X−2 dt
for some constants Cn. Now using the initial condition we have:
c(ζ, 0) =
∞∑
n=0
Cn cos
(
(2n+ 1)piζ
2
)
= 1 (24)
6.2.4 The Orthogonality Integral
Remembering the orthogonality properties of cosines:
∫ 1
0
cos
(
(2n+ 1)piζ
2
)
cos
(
(2m+ 1)piζ
2
)
dζ =

0 if n 6= m
1/2 if n = m 6= 0
1 if n = m = 0
for integers n,m. Then integrating both sides after multiplying (24) by cos
(
(2m+1)piζ
2
)
,
we have:∫ 1
0
cos
(
(2m+ 1)piζ
2
)
dζ =
∞∑
n=0
Cn
∫ 1
0
cos
(
(2n+ 1)piζ
2
)
cos
(
(2m+ 1)piζ
2
)
dζ
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= Cm/2
therefore:
Cm = 2
∫ 1
0
cos
(
(2m+ 1)piζ
2
)
dζ =
4
(2m+ 1)pi
[
sin
(
(2m+ 1)piζ
2
)]ζ=1
ζ=0
so that
Cm =
4(−1)m
(2m+ 1)pi
The solution reads:
c(ζ, τ) =
4
pi
∞∑
n=0
(−1)n
(2n+ 1)
L
X(τ)
cos
(
(2n+ 1)piζ
2
)
e−D(
(2n+1)pi
2 )
2 ∫ τ
0
X−2 dt (25)
6.3 Fractional Drug Release ODE
We may make use of the original PDE (7) and the boundary and initial conditions (8)
to construct an ODE for the fractional drug release over time M(τ). The definition
of M(τ) implies that: ∫ 1
0
c(ζ, τ) dζ = (1−M(τ)) L
X
in addition the initial condition implies:∫ 1
0
c(ζ, 0) dζ = 1 = (1−M(0)) L
X(0)
⇒M(0) = 0
therefore take the space integral between zero and one for the PDE (7), we get:
∂
∂τ
∫ 1
0
c(ζ, τ) dζ =
D
X2
∫ 1
0
∂2c
∂ζ2
dζ − X˙
X
∫ 1
0
c(ζ, τ) dζ
or
d
dτ
(1−M(τ)) L
X
+
X˙
X
(1−M(τ)) L
X
=
D
X2
[
∂c(1, τ)
∂ζ
− ∂c(0, τ)
∂ζ
]
giving:
− L
X
dM(τ)
dτ
− LX˙
X2
(1−M(τ)) + LX˙
X2
(1−M(τ)) = D
X2
cζ(1, τ)
therefore:
dM(τ)
dτ
= − D
LX
cζ(1, τ)
so that:
M(τ) = −D
L
∫ τ
0
cζ(1, t)
X(t)
dt ≡ −D
L2
∫ τ
0
cζ(1, t)
f(t)
dt
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6.4 Variation with Half-Life
6.4.1 The Static Case
Note that the expression for the fractional drug release over time for the static case
reads:
MS(τ) = 1−
∞∑
n=0
8
(2n+ 1)2pi2
e−D(
(2n+1)pi
2L )
2
τ
= 1− 8
pi2
e−
(
pi
√
Dτ
2L
)2
+
1
9
e
−
(
3pi
√
Dτ
2L
)2
+
1
25
e
−
(
5pi
√
Dτ
2L
)2
+ ...

for small time the first of these terms remains the largest so that:
MS(τ) ' 1− 8
pi2
e−D(
pi
2L)
2
τ
note that the fractional drug release reaches its half way point for a time τhf given
by:
1
2
= 1− 8
pi2
e−D(
pi
2L)
2
τhf
so that
τhf = − 4L
2
pi2D
ln
(
pi
4
)2
(26)
which for D = L = 1 gives τhf ' 0.2, which if taken on the τ 1/2 coordinate line
gives
√
τhf ' 0.44. This coincides quite well with the estimated deviation time of
the relative difference between the analytical and small time solutions.
6.4.2 Linear Growth
A similar calculation shows that for the linear dynamic case, equation (14):
τhf =
− 1
D
(
2L
pi
)2
ln
(
pi
4
)2
1 + r
D
(
2L
pi
)2
ln
(
pi
4
)2
which coincides with the static case when r = 0. This is valid provided r 6=
−D(pi/2L)2/ ln(pi/4)2.
6.4.3 Exponential Growth
Again, the same calculation for the exponential dynamic case, equation (16), obtains:
τhf = − 1
2r
ln
(
1 +
2r
D
(
2L
pi
)2
ln
(
pi
4
)2)
for r 6= 0 and in fact r > −(D/2)(pi/2L)2/ ln(pi/4)2.
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static linear exponential
r thf
√
thf thf
√
thf thf
√
thf
0 0.20 0.44 0.20 0.44 NA NA
1 NA NA 0.25 0.50 0.25 0.50
2 NA NA 0.33 0.57 0.38 0.62
3 NA NA 0.50 0.70 NA NA
4 NA NA 1.00 1.00 NA NA
Table 2: Table showing the time required for half of the drug to be released for the
static and dynamic cases using L = D = 1. Here, NA means Not Applicable.
6.4.4 Logistic Growth
For the logistic case an exact expression for the half-life cannot be obtained given
the mix of time terms involved in equation (18).
The half-lives for the static, linear and exponential cases, for L = D = 1, are
shown in Table 2. These results match well the times which can be read off the
graphs of Figure 9.
6.5 Fractional Drug Release for General X at Small Times
We have:
M(τ) = 1−
∞∑
n=0
8
(2n+ 1)2pi2
e−D(
(2n+1)pi
2L )
2
I
for
I(τ) =
∫ τ
0
f(t)−2 dt
now, assume that f may be expanded in a Taylor series about t = 0 as:
f(t) ' f(0) + f ′(0)t+ f
′′(0)t2
2!
+O(t3)
then up to first order we have:
I(τ) =
∫ τ
0
f(t)−2 dt '
∫ τ
0
[f(0) + f ′(0)t]−2 dt
=
1
[f(0)]2
∫ τ
0
[
1 +
f ′(0)
f(0)
t
]−2
dt
' 1
[f(0)]2
∫ τ
0
1− 2f
′(0)
f(0)
t dt
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=
τ
[f(0)]2
− f
′(0)
[f(0)]3
τ 2
Now since for any function representing the growing boundary f(0) = 1. Therefore
for any such function at small times it ‘looks’ like the static case:
M(τ) ' 1−
∞∑
n=0
8
(2n+ 1)2pi2
e−D(
(2n+1)pi
2L )
2
τ
for small times which implies that
M(τ) =
2
L
√
D
pi
τ 1/2
for any kind of dynamic boundary with f(τ) ≥ 1 for τ ≥ 0.
6.6 Taylor Series Expansion of D(t)
D
(
X(t)
L
)
= D
(
X(0)
L
)
+
dD
dt
∣∣∣∣∣
t=0
t+ ...
but since at X(0) = L:
dD
dt
=
dD
d(X/L)
d(X/L)
dt
=
D′(X/L)X˙(t)
L
then
D(X(t)/L) = D(1) +
(
D′(1)X˙(0)
L
)
t+ ...
then the integral up to second order in time is
T =
∫ t
0
D(X(t′)/L) dt′ '
∫ t
0
D(1) +
(
D′(1)X˙(0)
L
)
t′ dt′
= D(1)t+
(
D′(1)X˙(0)
2L
)
t2
similarly the integral ∫ T
0
X(t)−2 dt ' 1
X(0)2
(
T − X˙(0)
X(0)
T 2
)
substituting for T
∫ T
0
X(t)−2 dt =
1
X(0)2
D(1)t+ (D′(1)X˙(0)
2L
)
t2 − X˙(0)
X(0)
(
D(1)t+
(
D′(1)X˙(0)
2L
)
t2
)2
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6.7 Sum to n Terms of M(τ)
Given the general solution to fractional drug release:
M(τ) = 1−
∞∑
n=0
8
(2n+ 1)2pi2
e−D(
(2n+1)pi
2L )
2
I
where I(τ) =
∫ τ
0 f(t)
−2 dt. Then the sum becomes:
M(τ) = 1− 8
pi2
e−D(
pi
2L)
2
I −
∞∑
n=1
8
(2n+ 1)2pi2
e−D(
(2n+1)pi
2L )
2
I
the second sum may be summed to n terms with use of the integral test of Calculus,
that is, the convergence and the sum to n terms may be expressed through the
integral:
8
pi2
∫ ∞
n
e−D(
(2x+1)pi
2L )
2
I
(2x+ 1)2
dx
now let y =
√
DI(2x + 1)pi/2L, dy =
√
DIpidx/L, x : n → ∞, y : √DI(2n +
1)pi/2L→∞. We have:
2
√
DI
piL
∫ ∞
(2n+1)
√
DIpi
2L
e−y
2
y2
dy
the integral may be solved by integration by parts by setting:
u = e−y
2
, du = −2ye−y2 dy; dv = y−2dy ⇒ v = −y−1
or: ∫ ∞
(2n+1)
√
DIpi
2L
e−y
2
y2
dy = − e
−y2
y
∣∣∣∣∣
∞
(2n+1)
√
DIpi
2L
−
∫ ∞
(2n+1)
√
DIpi
2L
2ye−y
2
y
dy
=
2Le−D(
(2n+1)pi
2L )
2
I
√
DI(2n+ 1)pi
− 2
∫ ∞
(2n+1)
√
DIpi
2L
e−y
2
dy
the integral on the right is an error function [3], i.e.
2√
pi
∫ ∞
z
e−x
2
dx = erfc z
in fact we get:
=
2Le−D(
(2n+1)pi
2L )
2
I
√
DI(2n+ 1)pi
−√pierfc
(
(2n+ 1)
√
DIpi
2L
)
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the final solution is then:
2
√
DI
piL
∫ ∞
(2n+1)
√
DIpi
2L
e−y
2
y2
dy =
4e−D(
(2n+1)pi
2L )
2
I
(2n+ 1)pi2
− 2
L
√
DI
pi
erfc
(
(2n+ 1)
√
DIpi
2L
)
therefore the sum up to n terms (n = 1, 2, 3, ...) of M(τ) is:
M(τ) = 1− 8
pi2
e−D(
pi
2L)
2
I − 4e
−D( (2n+1)pi2L )
2
I
(2n+ 1)pi2
+
2
L
√
DI
pi
erfc
(
(2n+ 1)
√
DIpi
2L
)
(27)
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